Percutaneous trial lead placement, epidural threading to T8–T10, and paresthesia mapping across tonic, burst, and 10 kHz waveforms
Spinal cord stimulation (SCS) is a reversible, trial-first neuromodulation therapy reserved for chronic neuropathic or mixed pain refractory to conservative and interventional management — most classically failed back surgery syndrome (FBSS) and complex regional pain syndrome (CRPS). The defining, guideline-mandated feature of SCS is a temporary percutaneous trial before any permanent implant, allowing the patient to experience the therapy's real-world effect before committing to surgery.
SCS is indicated for chronic (>6 months), predominantly neuropathic pain that has failed conservative and less-invasive interventional treatment, most commonly:
• Failed back surgery syndrome (FBSS) / persistent spinal pain syndrome type 2 — the single largest indication, particularly for predominant leg (radicular) pain rather than purely axial back pain, where SCS traditionally performs less well • Complex regional pain syndrome (CRPS) type I and II — strong evidence base including randomized trial data • Painful diabetic peripheral neuropathy — an FDA-approved indication for high-frequency (10 kHz) stimulation • Chronic ischemic limb pain / refractory angina in select international practice
Multidisciplinary evaluation per NANS (North American Neuromodulation Society) consensus includes: • Comprehensive psychological evaluation — untreated major depression, active suicidal ideation, unresolved secondary gain issues, or uncontrolled substance use disorder are relative or absolute contraindications requiring treatment before proceeding • Confirmation that pain is neuropathic or mixed (nociceptive-only axial back pain without radicular component responds less predictably) • Exhaustion of reasonable conservative measures: physical therapy, medication optimization, and typically prior interventional procedures (ESI, RFA) as appropriate to the pain generator • Absence of anticoagulation that cannot be safely held, active systemic infection, and uncorrected coagulopathy
Unlike most surgical implants, spinal cord stimulation is unique in requiring a temporary, externalized trial period before committing to a permanent implantable pulse generator (IPG). This reflects the highly variable, subjective, and patient-specific nature of paresthesia coverage and pain relief:
• A percutaneous trial lead is placed in an outpatient or ambulatory surgery setting, connected to an external trial stimulator worn on a belt • The patient goes home for a defined trial period (typically 3-10 days, occasionally up to 2 weeks depending on payer requirements and clinical practice) • Only if the trial demonstrates a clinically meaningful response (conventionally ≥50% pain reduction, and/or significant functional improvement, reduced opioid use, improved sleep) does the patient proceed to permanent IPG implantation • This two-stage approach avoids implanting a costly, invasive, permanent device in patients who ultimately would not benefit — trial failure rates of 20-30% are not uncommon depending on indication, meaning the trial step meaningfully changes management in a substantial minority of patients
Because roughly one in four to one in three trials do not proceed to permanent implantation, the trial period is not a formality — it is the primary determinant of whether this invasive, costly therapy is pursued at all.
Trial lead placement begins with epidural access using the same loss-of-resistance principle as interlaminar epidural injections, but with a large-bore Tuohy needle angled shallowly to allow subsequent cephalad threading of a flexible cylindrical lead — entry is deliberately chosen well below the conus medullaris to avoid spinal cord injury during needle passage.
Positioning: prone on a radiolucent fluoroscopy table, arms forward, with a pillow under the abdomen to flex the lumbar spine and open the interlaminar space, identical setup to interlaminar epidural steroid injection.
Entry level selection: for a target lead tip at T8-T10 (standard for low back and bilateral leg coverage), needle entry is chosen 2-3 vertebral levels caudal to the target — typically T12-L1 or L1-L2 — for two reasons: 1. Safety: this is well below the adult conus medullaris (which typically terminates around the L1-L2 disc space, though anatomic variation exists), minimizing risk of direct spinal cord injury during needle passage 2. Trajectory mechanics: a shallow needle angle (~45° to skin) at a lower entry level allows the needle bevel, and subsequently the flexible lead, to be directed cephalad within the epidural space toward the thoracic target without excessive lead curvature
Needle advancement: paramedian approach is generally preferred over strict midline for SCS trials, since the paramedian trajectory provides a shallower, more favorable angle for cephalad lead passage and reduces the chance of midline interspinous ligament resistance mimicking loss-of-resistance.
Loss-of-resistance: identical physiology to standard epidural access — saline or air LOR technique confirms passage through the ligamentum flavum into the dorsal epidural space, verified on lateral fluoroscopic view showing the needle tip just past the ligamentum flavum, anterior to the lamina, posterior to the thecal sac.
Before any lead is passed through the Tuohy needle, several confirmatory steps are essential:
• Lateral fluoroscopic confirmation: the needle tip should sit in the dorsal (posterior) epidural space, not have inadvertently punctured the dura (no CSF return on aspiration) or advanced too far anteriorly • Needle bevel orientation: the Tuohy bevel is oriented cephalad (toward the target level) to direct the flexible lead in the desired direction as it exits the needle tip • For bilateral or multi-lead trials (common in modern practice using two parallel leads for enhanced coverage and later cross-talk stimulation options), two separate needle entries are used, typically one level apart or via a single entry with two lateral paramedian passes • Contrast is not routinely required for SCS lead placement (unlike diagnostic epidural injections) since the needle's successful LOR and the subsequent fluoroscopically-visualized radiopaque lead itself provide direct visual confirmation of the epidural trajectory
Once epidural access is confirmed, a flexible, multi-contact cylindrical ("octrode") lead is advanced cephalad through the Tuohy needle under continuous fluoroscopic guidance, requiring careful midline positioning on AP view and confirmed dorsal placement on lateral view — the T8-T10 vertebral body range is the classic target for combined low back and bilateral leg pain coverage.
Percutaneous trial leads are flexible, cylindrical, multi-contact electrodes (typically 8 contacts per lead, sometimes paired as dual parallel 8-contact leads for a combined 16-contact array) designed to be threaded through a Tuohy needle without a surgical laminotomy.
Mechanism — the gate control theory and dorsal column physiology: • SCS electrically stimulates the large-diameter, myelinated Aβ fibers of the dorsal columns (fasciculus gracilis and cuneatus), which carry proprioceptive and light-touch information • Per Melzack and Wall's gate control theory (1965) and subsequent refinements, activating these large fibers is believed to inhibit transmission of nociceptive signals carried by smaller Aδ and C fibers at the dorsal horn, producing analgesia • Newer sub-perception waveforms (burst, 10 kHz) appear to work through additional mechanisms beyond simple gate control, including modulation of wide-dynamic-range neurons and descending inhibitory pathways, though exact mechanisms remain an active area of research
Because the dorsal columns are somatotopically organized (fibers from lower extremities positioned more medially/deeply, trunk fibers more laterally within the tract), precise lead position — both rostrocaudal level and mediolateral placement — directly determines which body regions experience paresthesia coverage.
Lead advancement is a careful, incremental process performed under continuous or frequent fluoroscopic spot-checking:
1. The lead is fed through the Tuohy needle hub and advanced cephalad in the epidural space, using the natural curve of the needle bevel and gentle rotation to navigate cephalad without buckling 2. AP view: the lead should track in the midline, directly over or immediately adjacent to the spinous processes — significant lateral deviation suggests the lead has drifted into a lateral gutter or nerve root sleeve rather than remaining in the dorsal midline epidural space 3. Lateral view: the lead should remain in the posterior third of the spinal canal, staying dorsal to (behind) the thecal sac — a lead that appears to be tracking anteriorly or crossing the canal suggests inadvertent subdural or more ventral placement 4. For low back and bilateral leg coverage (the most common FBSS pattern), the active contact array is positioned to span approximately the T8 to T10 vertebral body level, which corresponds to the dorsal column afferents for the lumbosacral dermatomes 5. Once satisfactory position is achieved on both views, the lead is anchored temporarily (for trial) with a light adhesive dressing, or with a small anchor and strain-relief loop if a formal trial anchor technique is used, and the Tuohy needle is carefully withdrawn over the lead without displacing it — a step requiring particular care as needle withdrawal can inadvertently pull the lead backward if not stabilized
With the lead in an anatomically reasonable position, the patient is kept awake (light or no sedation) so that real-time stimulation can be tested and the lead fine-tuned until the subjective paresthesia — a tingling or buzzing sensation — overlaps as completely as possible with the distribution of the patient's clinical pain, a step unique to conventional tonic stimulation but bypassed with paresthesia-free waveforms.
For conventional tonic stimulation, intraoperative paresthesia mapping is the critical fine-tuning step that determines trial success:
1. The externalized trial stimulator is connected and activated at low amplitude, sequentially testing different contact combinations (bipolar and tripolar configurations) along the lead 2. The patient reports, in real time, where they feel the paresthesia — described as tingling, buzzing, or a gentle vibration — using body diagrams or verbal description 3. The proceduralist compares the paresthesia map to the patient's pre-procedure pain diagram, aiming for maximal overlap, particularly ensuring bilateral leg coverage is achieved (often requiring dual parallel leads with independently steerable current if unilateral coverage predominates with a single lead) 4. If overlap is inadequate, the lead position is adjusted in small (1-2 mm) increments — cranial/caudal movement changes the rostrocaudal coverage level, while subtle lateral repositioning or use of a second parallel lead adjusts left-right symmetry 5. This process is iterative and may take 20-45 minutes intraoperatively to optimize, since patient-reported paresthesia location can shift meaningfully with even millimeter-scale lead movements, reflecting the fine somatotopic organization of the dorsal columns
Adequate paresthesia-pain overlap (generally >80% of the painful area covered) during intraoperative mapping is strongly correlated with, though not a perfect predictor of, ultimate trial success.
Modern SCS systems allow the trial to test multiple stimulation paradigms, each with a distinct mechanism and clinical profile:
• Tonic stimulation (conventional, 40-60 Hz, pulse width 200-450 μs): the original paradigm, produces paresthesia that the patient consciously feels; requires the intraoperative mapping process described above; efficacy is well-established over decades of clinical use, particularly for FBSS leg pain
• Burst stimulation (groups/"bursts" of 5 spikes at 500 Hz repeated at 40 Hz, mimicking natural thalamic burst firing patterns): produces minimal or no paresthesia in many patients while still providing analgesia; some studies (SUNBURST trial) suggest comparable or superior pain relief to tonic stimulation with less paresthesia-related discomfort, useful for patients who find tonic paresthesia unpleasant or who experience positional paresthesia fluctuation
• High-frequency 10 kHz stimulation (HF10, Nevro Senza system, FDA-approved primarily for back and leg pain and painful diabetic neuropathy): stimulates at 10,000 Hz, sub-perception threshold, producing pain relief without any paresthesia at all — this eliminates the need for intraoperative paresthesia mapping since coverage is verified by empirical pain relief reporting over the trial period rather than real-time sensation location, and allows lead placement to proceed with the patient under light sedation
Many contemporary trials test more than one waveform during the same trial period, allowing the patient to compare tonic, burst, and/or high-frequency stimulation and select their preferred paradigm before permanent implantation — a personalized approach reflecting substantial patient-to-patient variability in waveform preference.
The externalized trial period — typically 3 to 10 days at home with the leads exiting the skin and connected to an external stimulator — is the definitive test of whether spinal cord stimulation will meaningfully help this specific patient, evaluated against a structured ≥50% pain relief threshold alongside functional and quality-of-life measures before committing to permanent implantation.
During the externalized trial period, the patient is discharged home with the percutaneous leads secured and connected via extension cables to an external trial stimulator, and is asked to:
• Resume normal daily activities as much as possible (within reasonable restrictions on bending, twisting, and heavy lifting that could dislodge the trial leads) to obtain a realistic assessment of benefit during real-world function, not just at rest • Keep a structured pain diary tracking numeric pain scores (0-10) multiple times daily, comparing pre-trial baseline to on-stimulation levels • Track functional outcomes: sleep quality, medication (particularly opioid) use, ability to perform activities of daily living, and overall satisfaction • Trial durations vary by practice pattern and payer requirement — most commonly 3-7 days, occasionally extended to 10-14 days — balanced against the cumulative infection risk of externalized hardware, which rises with trial duration • The patient typically returns for lead removal (a simple bedside procedure, pulling the percutaneous lead out through the skin) at the end of the trial period, regardless of outcome, since trial leads are not intended for long-term implantation
Success is not judged on stimulation sensation alone — a patient may have excellent paresthesia-pain overlap intraoperatively yet report insufficient pain relief during real-world trial use, underscoring why the take-home trial period, not just intraoperative mapping, is the true test.
NANS (North American Neuromodulation Society) consensus and most payer policies define a successful trial as:
• ≥50% reduction in pain intensity (by numeric rating scale or visual analog scale) compared to pre-trial baseline, sustained across the trial period, AND/OR • Clinically meaningful functional improvement — reduced opioid consumption, improved sleep, increased activity tolerance, and patient-reported satisfaction — since pain scores alone can be an incomplete measure of benefit
If the trial meets these criteria, the patient proceeds to permanent implantation: • A definitive lead (percutaneous or surgical paddle-type, the latter often preferred for permanent implants due to more stable long-term positioning and lower migration risk) is placed at the level validated during the trial • An implantable pulse generator (IPG) — either primary-cell (non-rechargeable, replaced every 3-7 years depending on usage) or rechargeable (lasting 8-10+ years with periodic external recharging) — is implanted subcutaneously, typically in the buttock or flank • Programming is refined over subsequent follow-up visits, often incorporating the waveform (tonic/burst/10kHz) preference identified during the trial
If the trial fails to meet the threshold, the leads are removed and permanent implantation is not pursued — sparing the patient a surgical procedure and device cost without corresponding benefit, and prompting reconsideration of the underlying pain diagnosis or alternative treatment pathways (e.g., dorsal root ganglion stimulation, intrathecal drug delivery, or continued multimodal pain management).
Failed back surgery syndrome patients with predominantly axial (rather than radicular/leg) pain historically show lower SCS trial success rates, which has driven interest in dorsal root ganglion (DRG) stimulation and newer waveforms for axial-predominant pain phenotypes — patient selection and pain phenotype remain the strongest predictors of trial success.